Datum: 18.7.2008
The unwanted growth of blood vessels is a key feature of a number of serious diseases including cancers, arthritis and macular degeneration. While there are a number of drugs that effectively inhibit the angiogenesis, or growth, of these vessels some only target a limited number of receptor or have unacceptable side affects.
A team at Boston Children's Hospital have now succeeded in reformulating a broad-spectrum angiogenesis inhibitor, TNP-470, using a nanotechnology approach into a form that can be taken orally and that has the potential to be used as a preventative or maintenance therapy for a variety of cancers.
Whole article nanomednet
BIOFORUM 2010
Lodz, Poland, May 19-21, 2010
Mendel lectures: How DNA recombination maintains genome integrity
Mendel museum, Brno, April 15, 2010
Mendel lectures: Germ cell specification in mice
Mendel museum, Brno, April 29, 2010
The Second International Conference on Biological and Environmental Sciences (2ICBES)
Mansoura and Luxor, Egypt, March 15-20, 2010
XGen Congress
San Diego, CA, United States, March 15-19, 2010
Drug Discovery Technology World Asia 2010
Singapore, March 16-19, 2010
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
© 2006 South Moravian Innovation Centre
Interesting biotechnology content:
Biotechnology portal - at Wikipedia. Useful information for you.
Biotechnology legislative - Biotech legislative environment search
Gene Variation That Lets People Get by on Fewer Zees Is Transferred into Mice
Cocaine Vaccine Shows Promise for Treating Addiction